| pubmed-article:8635937 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8635937 | lifeskim:mentions | umls-concept:C1522449 | lld:lifeskim |
| pubmed-article:8635937 | lifeskim:mentions | umls-concept:C0030797 | lld:lifeskim |
| pubmed-article:8635937 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:8635937 | lifeskim:mentions | umls-concept:C0069454 | lld:lifeskim |
| pubmed-article:8635937 | lifeskim:mentions | umls-concept:C0206034 | lld:lifeskim |
| pubmed-article:8635937 | lifeskim:mentions | umls-concept:C1444657 | lld:lifeskim |
| pubmed-article:8635937 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:8635937 | pubmed:dateCreated | 1996-7-10 | lld:pubmed |
| pubmed-article:8635937 | pubmed:abstractText | A randomized clinical trial from Great Britain suggested a possible beneficial effect of acetylsalicylate in the prevention of radiation-induced bowel toxicity. Olsalazine is an orally administered drug designed to deliver 5-aminosalicylate to the large bowel with minimal systemic absorption. A randomized clinical trial was undertaken to assess the effectiveness of olsalazine in preventing acute diarrhea in patients receiving pelvic radiation therapy. | lld:pubmed |
| pubmed-article:8635937 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8635937 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8635937 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8635937 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8635937 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8635937 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8635937 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8635937 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8635937 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8635937 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8635937 | pubmed:month | May | lld:pubmed |
| pubmed-article:8635937 | pubmed:issn | 0360-3016 | lld:pubmed |
| pubmed-article:8635937 | pubmed:author | pubmed-author:MoertelC GCG | lld:pubmed |
| pubmed-article:8635937 | pubmed:author | pubmed-author:O'FallonJ RJR | lld:pubmed |
| pubmed-article:8635937 | pubmed:author | pubmed-author:TewfikH HHH | lld:pubmed |
| pubmed-article:8635937 | pubmed:author | pubmed-author:MooreR LRL | lld:pubmed |
| pubmed-article:8635937 | pubmed:author | pubmed-author:HylandGG | lld:pubmed |
| pubmed-article:8635937 | pubmed:author | pubmed-author:FrankA RAR | lld:pubmed |
| pubmed-article:8635937 | pubmed:author | pubmed-author:MortonR FRF | lld:pubmed |
| pubmed-article:8635937 | pubmed:author | pubmed-author:MailliardJ... | lld:pubmed |
| pubmed-article:8635937 | pubmed:author | pubmed-author:CollinsR TRT | lld:pubmed |
| pubmed-article:8635937 | pubmed:author | pubmed-author:MartensonJ... | lld:pubmed |
| pubmed-article:8635937 | pubmed:author | pubmed-author:DemingR LRL | lld:pubmed |
| pubmed-article:8635937 | pubmed:author | pubmed-author:UriasR ERE | lld:pubmed |
| pubmed-article:8635937 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8635937 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:8635937 | pubmed:volume | 35 | lld:pubmed |
| pubmed-article:8635937 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8635937 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8635937 | pubmed:pagination | 299-303 | lld:pubmed |
| pubmed-article:8635937 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:8635937 | pubmed:meshHeading | pubmed-meshheading:8635937-... | lld:pubmed |
| pubmed-article:8635937 | pubmed:meshHeading | pubmed-meshheading:8635937-... | lld:pubmed |
| pubmed-article:8635937 | pubmed:meshHeading | pubmed-meshheading:8635937-... | lld:pubmed |
| pubmed-article:8635937 | pubmed:meshHeading | pubmed-meshheading:8635937-... | lld:pubmed |
| pubmed-article:8635937 | pubmed:meshHeading | pubmed-meshheading:8635937-... | lld:pubmed |
| pubmed-article:8635937 | pubmed:meshHeading | pubmed-meshheading:8635937-... | lld:pubmed |
| pubmed-article:8635937 | pubmed:meshHeading | pubmed-meshheading:8635937-... | lld:pubmed |
| pubmed-article:8635937 | pubmed:meshHeading | pubmed-meshheading:8635937-... | lld:pubmed |
| pubmed-article:8635937 | pubmed:meshHeading | pubmed-meshheading:8635937-... | lld:pubmed |
| pubmed-article:8635937 | pubmed:meshHeading | pubmed-meshheading:8635937-... | lld:pubmed |
| pubmed-article:8635937 | pubmed:meshHeading | pubmed-meshheading:8635937-... | lld:pubmed |
| pubmed-article:8635937 | pubmed:meshHeading | pubmed-meshheading:8635937-... | lld:pubmed |
| pubmed-article:8635937 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:8635937 | pubmed:articleTitle | Olsalazine is contraindicated during pelvic radiation therapy: results of a double-blind, randomized clinical trial. | lld:pubmed |
| pubmed-article:8635937 | pubmed:affiliation | Mayo Clinic, Rochester, MN 55905, USA. | lld:pubmed |
| pubmed-article:8635937 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8635937 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8635937 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:8635937 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8635937 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8635937 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8635937 | lld:pubmed |
